Abstract: An outlier IC detection method includes acquiring first measured data of a first IC set, training the first measured data for establishing a training model, acquiring second measured data of a second IC set, generating predicted data of the second IC set by using the training model according to the second measured data, generating a bivariate dataset distribution of the second IC set according to the predicted data and the second measured data, acquiring a predetermined Mahalanobis distance on the bivariate dataset distribution of the second IC set, and identifying at least one outlier IC from the second IC set when at least one position of the at least one outlier IC on the bivariate dataset distribution is outside a range of the predetermined Mahalanobis distance.

Abstract: The present invention relates to the newly identified cancer therapeutic targets and biomarkers. These targets/biomarkers are overexpressed in carcinomas generally, and more specifically to adenocarcinoma and squamous cell carcinoma. The invention provides methods of diagnosis, characterization, and therapy of carcinoma based on the degree of overexpression of the targets/biomarkers.

Abstract: The present invention relates to the newly identified cancer therapeutic targets and biomarkers. These targets/biomarkers are overexpressed in carcinomas generally, and more specifically to adenocarcinoma and squamous cell carcinoma. The invention provides methods of diagnosis, characterization, and therapy of carcinoma based on the degree of overexpression of the targets/biomarkers.

Abstract: The present invention relates to the newly identified cancer therapeutic targets and biomarkers. These targets/biomarkers are overexpressed in carcinomas generally, and more specifically to adenocarcinoma and squamous cell carcinoma. The invention provides methods of diagnosis, characterization, and therapy of carcinoma based on the degree of overexpression of the targets/biomarkers.

Abstract: A method of increasing the number of activated astrocytes in a subject. The method involves identifying a subject suffering from or being at risk for developing a neurodegenerative disease and administering to the subject an effective amount of an agonist of the A2A-adenosine receptor. Also disclosed are a method of treating a neurodegenerative disease, a packaged product for treating a subject suffering from or being at risk for developing a neurodegenerative disease, and a method of identifying an agonist of the A2A-adenosine receptor for treating a neurodegenerative disease.